深圳商报·读创客户端记者 李耿光 港交所官网显示，6月6日，北京先通国际医药科技股份有限公司（以下简称"先通医药"）公告，进一步委任广发证券（香港）经纪有限公 司、星展亚洲融资有限公司及招银国际融资有限公司为其整体协调人。此前的5月26日，先通医药已向港交所主板递交上市申请，中金公司 （601995）和中信证券为联席保荐人。 | [編纂]項下的[编纂]數目 | : [编纂]H股(視乎[编纂]行使與否而定) | | --- | --- | | [編纂]數目 ። | [编纂]H股(可于重新分配) | | [编纂]數目 | [编纂]股H股(可予重新分配及視乎[编纂]行 | | | 使否而定) | | 最高[编纂] : | 每股H股[编纂]港元,另加1%經紀佣金、 | | | 0.0027% 證監會交易徵費、0.00015% 會財局 | | | 交易徴費及0.00565% 香港聯交所交易費(須 | | | 於申請時以港元繳足,多繳款項可予退還) | | 面值 : | 每股H股人民幣1.00元 | | 【霜景】：【漏景】 | | | 聯席保薦人、[編纂]、 | | | [编纂] | | 招股书显示，先通医药成立于200 ...

Core Viewpoint - Beijing Xiantong International Pharmaceutical Technology Co., Ltd. (referred to as "Xiantong Pharmaceutical") has officially submitted its prospectus to the Hong Kong Stock Exchange (HKEX) for an IPO, aiming to become the first listed company in the radioactive drug sector in Hong Kong [1][3] Financial Performance - For the fiscal years ending December 31, 2023, and 2024, Xiantong Pharmaceutical reported revenues of approximately RMB 10.23 million and RMB 44.06 million, respectively, with net losses of about RMB 309.23 million and RMB 156.12 million [2][5] - The company anticipates significant operating losses and expenses in the coming years as it advances its clinical research and seeks regulatory approvals for its candidate products [5][6] Product Pipeline and Market Position - Xiantong Pharmaceutical is a leader in China's radioactive drug market, focusing on the development and commercialization of innovative radioactive drugs, with a pipeline that includes 15 assets targeting oncology, neurodegenerative diseases, and cardiovascular diseases [3][4] - The company has launched two products: XTR005, the first approved PET tracer targeting Aβ in China, and adenosine injection [4] Research and Development - R&D expenditures for 2023 and 2024 are projected at RMB 296.99 million and RMB 227.98 million, respectively, with core product development costs accounting for a significant portion of these expenses [7] - The company emphasizes the need for specialized knowledge and qualifications in various fields to develop radioactive drugs, indicating a commitment to building a professional team to meet these requirements [7][8] Industry Outlook - The global radioactive drug market is expected to grow from USD 9.7 billion in 2024 to USD 57.3 billion by 2035, with a compound annual growth rate (CAGR) of 17.5% [6] - The radioactive drug sector is gaining attention due to its potential for precise diagnosis and treatment, attracting continuous investment despite inherent challenges [6][8]

智通财经APP获悉，据港交所5月26日披露，北京先通国际医药科技股份有限公司(简称"先通医药")向港交所主板递交上市申请，中金 公司、中信证券为联席保荐人。招股书显示，根据灼识咨询报告，先通医药是中国首家获得创新放射性药物上市批准的企业。 XTR004是一种F标记的线粒体复合体I靶向的诊断用放射性配体，用于PET-心肌灌注成像("MPI")。XTR003是一种潜在的同类首创F标记 的PET诊断用放射性配体，用于心肌脂肪酸代谢成像，以检测心肌存活性。 在先通医药的管线资产中，三项处于商业化或临近商业化阶段，八项处于临床或IND支持性阶段，及四项处于研究者发起的试验("IIT") 或临床前研究阶段。尤其是，公司的管线中包含四项潜在同类首创或同类最佳资产，以及四项基于2024年全球五大畅销放射性药物开 发的资产。 先通医药已建立两个自有的生产基地并已投产，其中一家位于江苏省无锡市，另一家位于广东省中山市。截至最后实际可行日期，该 等基地的总建筑面积("总建筑面积")超逾20,000平方米，设有共计12条商业规模生产线。此外，公司在四川省绵阳市另设有一个自有生 产基地，预计将于2025年第三季度开始投产。 上市产品方 ...